Dr. Reddy’s acquires rights to Investigational Anticancer Agent E7777 from Eisai

31 Mar 2016 Evaluate

Dr. Reddy’s Laboratories has entered into a licensing agreement with Eisai Co., Japan by which it will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai’s investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy’s holds the option for rights to develop and market the agent in India.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets. Through this agreement, the two companies aim to accelerate development and maximize the value of E7777.

Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1185.20 18.75 (1.61%)
20-Jan-2026 12:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1638.00
Dr. Reddys Lab 1185.20
Cipla 1378.40
Zydus Lifesciences 876.90
Lupin 2163.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×